Our story
Enzene Biosciences is a leading global contract development and manufacturing organization (CDMO), founded on the belief that we have a responsibility to positively impact healthcare worldwide.
Enzene provides technological expertise, fosters innovation, and is dedicated to helping clients bring accessible and affordable products to market. Our comprehensive capabilities include R&D, analytics, and GMP manufacturing, empowering us to provide innovative, high-quality solutions to solve today’s and tomorrow’s biotech challenges.
Our history
Our vision is to transform the landscape of global healthcare with innovative technologies and life-changing treatments.
We are achieving our vision by committing to innovation, quality, scalability, talent and responsibility.
Over the last decade we’ve experienced unparalleled levels of growth, and we’re not ready to stop yet.
Key milestones
Our growth trajectory is a testament to its strategic vision, resilience and excellence in the biopharmaceutical industry. Having achieved significant milestones in a short span of time, we have made impactful advancements, showcasing our commitment to innovation, quality, and global reach.
Established in 2015, Enzene Biosciences has grown from a 25,000 square feet facility in Pune, India, to a global organization with state-of-the-art R&D and clinical-scale GMP facilities in India and the US. Our commercial success includes seven biosimilar products commercialized in under three years, and our patented technology for continuous manufacturing, EnzeneX™.
What’s next?
- We're establishing our commercial-scale GMP facility in the US.
- We will have multiple 2000L manufacturing suites for clinical and commercial manufacturing.
- We're increasing the scale in our GMP microbial GMP facility to 200L.
- We're registering Denosumab in the US and the EU, Teriparatide in the EU and Liraglutide in the US.
2021 – 2023
- We successfully commercialized 7 biosimilars: Romiplostim, Teriparatide, Denosumab, Adalimumab, Cetuximab, Bevacizumab and Ranibizumab.
- We delivered GMP material for 4 Phase I clinical trials, including monoclonal antibodies and complex multi-specific proteins.
- We established a 2000L fed-batch manufacturing facility for clinical and commercial use.
2020
- We obtained commercial GMP certification for the manufacturing of E. coli mammalian-based products.
- Our microbial manufacturing facility passed QP auditing.
- We obtained 3 clinical trial approvals.
2019
- We developed EnzeneX™, our patented and validated continuous bioprocess manufacturing platform.
- Our GMP continuous manufacturing facility was established for monoclonal antibodies and recombinant proteins.
2015 – 2018
- Our end-to-end clone to formulation facility and clinical manufacturing facility were both established Pune, India.
- We obtained 7 pre-clinical project approvals and 3 clinical trial approvals.
Our people
We only bring the best to your project, and our world-class team of problem-solving pioneers has deep scientific and technical expertise across a wide range of modalities to help progress your innovation on its journey to the patients who need it most.
Our mission
Through a passionately progressive approach designed just for you, our cutting-edge services and productive pipeline of biosimilars cater to your project’s every need.
By continuously innovating and pushing boundaries, we strive to maximize your return on investment and help you bring trusted and affordable medicines to market at speed.
Join the revolution
Fueled by our continuous innovation and armed with EnzeneX™, our fully-integrated CDMO solutions and our biosimilars pipeline are designed to help bring your biologics innovations to life.